Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Blue Earth Diagnostics shortlisted for prestigious “Best Emerging Biotech Company” award

Oxford, UK – August 9, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Blue Earth Diagnostics appoints IASON Sp. z o.o. to manufacture and distribute Axumin® (fluciclovine (18F)) in Poland

Supports Blue Earth Diagnostics’ goal to make Axumin commercially available across Europe Oxford, UK –…

Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BURLINGTON, Mass. and OXFORD, UK, June 18, 2018 – Blue Earth Diagnostics, a molecular imaging…

Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics

– Unique attributes of rhPSMA and approved, commercially available Axumin® (fluciclovine F 18) for PET/CT…

Blue Earth Diagnostics opens new headquarters in Oxford

Expanded facility positions the company for future growth OXFORD, April 12, UK –, 2018 –Blue…

Blue Earth Diagnostics Announces Addition of Axumin® (Fluciclovine F 18) to NCCN Guidelines® for PET Imaging for Suspected Recurrent Prostate Cancer

- NCCN Guidelines aim to improve quality, effectiveness and efficiency of cancer care –  BURLINGTON,…

Blue Earth Diagnostics and GE Healthcare sign UK manufacturing agreement

Agreement marks first step towards full commercial availability of Axumin® (fluciclovine( 18F)) in the UK…